Ryan Cheu

Ryan Cheu

Dr. Ryan Cheu is a seasoned bioanalytical chemist and regulatory scientist with deep expertise in pharmacokinetics, method development, and pharmaceutical compliance. As Director of Chemistry at Emery Pharma, he leads the company’s bioanalytical and regulatory programs across both R&D and GLP/cGMP-compliant studies.

Related Posts:

Bioanalysis at Emery Pharma: Your Questions Answered

March 21, 2025

In the fast-paced world of drug development, bioanalysis plays a crucial role in determining a drug’s pharmacokinetics (PK) and pharmacodynamics (PD). At Emery Pharma, we specialize in providing high-quality bioanalytical services to support pharmaceutical and biotechnology companies at every stage…

Read More

Bridging Study: Comparing QQQ and HRMS for Impurity X Quantitation, determining their regulatory alignment, and evaluating method transfer feasibility

February 27, 2025

In pharmaceutical analysis, selecting the right instrumentation is critical for ensuring precise and regulatory-compliant impurity quantitation. At Emery Pharma, we conducted a bridging study to compare two mass spectrometry techniques—Triple Quadrupole Mass Spectrometry (QQQ) and High-Resolution Mass Spectrometry (HRMS)—for the…

Read More

An Overview of Nitrosated Drug Substance Related Impurities (NDSRIs)

October 25, 2024

Nitrosamines in Drug Substance (DS) In 2018, health authorities first detected the nitrosamine N-nitrosodimethylamine (NDMA) in valsartan drug substance. Investigations quickly expanded, and NDMA along with other carcinogenic nitrosamines were found in other members of the sartan drug family. By…

Read More

A Guide to Quantitative NMR (qNMR)

February 9, 2024

Quantitative NMR (qNMR) stands as a robust method for gauging pharmaceutical purity. In the realm of analytical chemistry, nuclear magnetic resonance (NMR) spectroscopy emerges as a potent technique, offering insights into the structure, dynamics, and interactions of organic molecules while…

Read More

Stability Study of Ranitidine

July 27, 2020

Emery Pharma presented this work at the 68th American Society for Mass Spectrometry (ASMS) Conference in June 2020. Ranitidine, an H2 histamine receptor blocker, is extensively used for heartburn and other stomach acid-related diseases. Recently, the detection of the probable…

Read More